Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,873,392 shares of BPMC stock, worth $543 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
5,873,392
Previous 6,250,823
6.04%
Holding current value
$543 Million
Previous $593 Million
6.76%
% of portfolio
0.08%
Previous 0.07%
Shares
15 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$614 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$604 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$299 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$227 Million8.22% of portfolio
-
State Street Corp Boston, MA2.38MShares$220 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.52B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...